Daily Brief Health Care: Bristol Myers Squibb Co, Shenzhen Mindray Bio-Medical Electronics and more

In today’s briefing:

Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments
Shenzhen Mindray Bio-Medical Electronics (300760.CH) 2022H1 – Waiting for the Next Jump in Valuation

Bristol-Myers Squibb: Acquisition of Turning Point Therapeutics & Other Developments

Bristol-Myers has continued its efforts towards expanding its new product range, in-line franchises, pipeline, and carried out critical business growth initiatives.
This result was fuelled by their in-line and new product portfolio’s 16% solid growth, which more than made up for their recent LOEs.
In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Mindray withstood the negative impact of pandemic/lockdown and continued to achieve solid growth in 2022H1 amid China’s “new infrastructure” projects and the recovery of overseas demand for routine medical care.
The essence of falling shares is the process of optimistic high growth expectations returning to rationality,which takes time until the cyclical shocks brought by the receding of pandemic are digested.
Mindray’s biggest alpha could be the change brought about by M&A. From the perspective of strategic development, the next jump in valuation is likely to depend on subsequent M&A performance.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network